Amyloid in the heart: An under-recognized threat at the interface of cardiology, haematology, and pathology

European Heart Journal Cardiovascular Imaging

Volumn 17, Issue 9, 2016, Pages 978-980

  Bonderman, Diana ^a   Agis, Hermine ^a   Kain, Renate ^a   Mascherbauer, Julia ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; CONGO RED; GADOLINIUM; IMMUNOGLOBULIN LIGHT CHAIN; PARAPROTEIN;

CARDIOLOGY; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; HEART AMYLOIDOSIS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE BIOPSY; HEMATOLOGY; HUMAN; PATHOLOGY; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; REVIEW; AMYLOIDOSIS; BLOOD; CARDIOMYOPATHIES; CINE MAGNETIC RESONANCE IMAGING; COMORBIDITY; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; NEEDLE BIOPSY; PROCEDURES; PROGNOSIS; PUBLIC RELATIONS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

ALLERGY AND IMMUNOLOGY; AMYLOIDOSIS; BIOPSY, NEEDLE; CARDIOLOGY; CARDIOMYOPATHIES; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HEMATOLOGY; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOHISTOCHEMISTRY; INTERPROFESSIONAL RELATIONS; MAGNETIC RESONANCE IMAGING, CINE; MALE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84992160830     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jew130     Document Type: Review

References (12)

1. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108:2520-30.
2. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349: 583-96.
3. Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015;126:612-5.
4. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al. Highdose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
5. Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P et al. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging 2016;9:126-38.
6. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015;132:1570-9.
7. Picken MM. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med 2010;134:545-51.
8. Bhatti S, Watts E, Syed F, Vallurupalli S, Pandey T, Jambekar K et al. Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 2016; 17:970-7.
9. Mohty D, Boulogne C, Magne J, Varroud-Vial N, Martin S, Ettaif H et al. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study. Eur Heart J Cardiovasc Imaging 2016;17:961-9.
10. Toor AA, Ramdane BA, Joseph J, Thomas M, O'Hara C, Barlogie B et al. Cardiac nonamyloidotic immunoglobulin deposition disease. Mod Pathol 2006;19:233-7.
11. Tosoni A, Barbiano di Belgiojoso G, Nebuloni M. Electron Microscopy in the Diagnosis of Amyloidosis. www.intechopen.com (22 September 2011, date last accessed).
12. Aschauer S, Kammerlander AA, Zotter-Tufaro C, Ristl R, Pfaffenberger S, Bachmann A et al. The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics. Eur J Heart Fail 2016;18:71-80.